Is the Benefit of China’s Zero-COVID Policy Worth the Cost?
The Chinese strategy may be more economically sound than many assume, but it is time for the country to adopt a less severe approach.
A nucleic acid test being performed in Shenzhen, China. Credit: Shengpengpeng Cai via Unsplash
Before COVID-19 vaccines were developed and distributed, China’s strict approach to controlling the virus resulted in fewer deaths and a much lower death rate per million people than in many other countries. But while these successes were impressive in late 2020 and early 2021, effective vaccines and treatments have become readily available since then, leading the World Health Organization to declare that the end of the pandemic is in sight.
Yet China has maintained its strict zero-COVID regime. While this containment strategy has saved many lives, it has also slowed the country’s economy, exacerbated supply-chain disruptions, and kept millions under lockdown for months. Does the zero-COVID policy pass a cost-benefit test in 2022?
China’s government and many investment banks had predicted that its economy would grow by roughly 5.5% in 2022, on the assumption that COVID-19 restrictions would be lifted. Instead, Chin
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Robert Lighthizer, the U.S. Trade Representative under Donald Trump, reflects on his decision to launch the trade war with China and begin the process of "strategic decoupling" — a process he says the U.S. must see through to the end.
